Method and kit for diagnosing myocardial infarction
AssigneeArtemis Proteomics, Ltd.
InventorsGeorge Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
Life of this patent
Estimating the term…
Abstract
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.
Claims5
A method for diagnosing myocardial infarction comprising:
- (a) conducting a mass spectrometric analysis on a sample obtained from a patient in a manner effective to maximize elucidation of discernible peptide fragments contained therein;
- and
- (b) comparing mass spectrum profiles of a peptide consisting of SEQ ID NO:1 to mass spectrum profiles of peptides elucidated from said sample;
- wherein recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for the peptide consisting of SEQ ID NO:1 is diagnostic for myocardial infarction.
The method of 1, wherein said sample is an unfractionated body fluid or a tissue sample.
The method of 1, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.
The method of 1, wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).
The method of 1, wherein said patient is a human.
Dependencies are inferred from the claim text.